DI-071 Linezolid use evaluation, pharmacy interventions and study of new optimisation points

• Published in: European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A145-A145
• Main Authors: Izquierdo, I Ibarrola, España, Z Perez, Barrenechea, LM Mendarte, Aguirre, I Martinez, Santos, NM Pardo, Urtizberea, U Blazquez, Diaz, I Loizaga, Muzas, E Oñate, Armada, A Llona, Ibarreche, MJ Yurrebaso
• Format: Article
• Language: English
• Subjects: Antibiotics; Bacteria; Drug interactions; Drug stores; Infections; Patients; Pharmacy
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2017-000640.318

BackgroundLinezolid is an antibiotic used for the treatment of serious infections caused by gram positive bacteria. Although first approved for skin infections, its use includes empiric treatment of infections usually caused by linezolid sensitive bacteria.PurposeTo describe, analyse and optimise the use of linezolid in a university hospital. To study new susceptible optimisation points.Material and methodsThis was a retrospective observational study (February–March 2016). Patient demographics and treatment related data were obtained from electronic clinical records. All linezolid prescriptions were reviewed, carrying out and registering pharmacy interventions. The results were compared with evidence observed in published guidelines and the literature.Results53 patients treated with linezolid were found (66 years (30–95)), 60% were men. Average treatment duration was 10.4 days (median 8 days, treatments longer than 90 days excluded). Indications were: 30% skin infections, 22.6% peritonitis, 18.8% pneumonia, 7.5% prosthesis infections and 7.5% meningitis. 51% of cases were unlabelled indications. 26.4% were empiric treatments (